Stay updated on Pembrolizumab in Triple Negative Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-05-01T01:46:39.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The webpage has undergone significant changes, including the removal of detailed information about a clinical trial for Pembrolizumab in treating metastatic triple negative breast cancer, while adding new identifiers and collaborators related to the study.
    Difference
    57%
    Check dated 2025-04-16T14:13:09.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T08:49:35.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T23:00:22.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1.0%
    Check dated 2025-02-24T20:28:41.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    1.0%
    Check dated 2025-02-10T09:38:45.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Triple Negative Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page.